Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.
Saudi generics and branded medicines supplier Tabuk Pharmaceuticals has struck a deal with Singapore-based Prestige BioPharma for the right to sell Prestige’s Tuznue (trastuzumab) biosimilar rival to Herceptin in the Middle East and North Africa region.
The licensing and distribution agreement gives Tabuk “exclusive rights to commercialize and distribute Tuznue in the MENA region, leveraging the...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
